Compare Honest Company Inc (HNST) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Honest Company Inc vs Organon & Co. Common Stock — how do they compare? Honest Company Inc trades at $5.05 (market cap $557.34M), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Organon & Co. Common Stock is far larger — about 6.5× Honest Company Inc's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Honest Company Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Honest Company Inc for 39 Days and Organon & Co. Common Stock for 0 Days on average.
| HNST | OGN | |
|---|---|---|
Market Cap | $557.34M | $3.62B |
Volume | 749,013 | 2,892,999 |
Sector | Consumer Staples | Health |
52-Week High | $5.95 | $13.81 |
52-Week Low | $2.10 | $5.70 |
Typical Hold Time | 39 Days | 0 Days |
Enterprise Value | $460.95M | $11.04B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HNST trades at $5.07, down 1.74% today, with mixed technical signals showing a neutral overall trend. The company reported Q2 2026 earnings beat with $0.04 EPS versus $0.00926 expected, though revenue declined year-over-year to $371.32M in 2025. Recent news highlights institutional buying from BlackRock and Deutsche Bank, while Seeking Alpha notes the company's turnaround progress through strategic exits and cost reductions.
The stock faces headwinds from negative profitability metrics (-3.56% net margin, -6.87% ROE) and elevated P/E of 48.83, but analyst consensus targets $5.30 with 30% buy ratings. Key risks include continued margin pressure and competitive threats in personal care, while potential upside hinges on sustained operational improvements and market share gains.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Honest Company Inc
The Honest Co Inc is a consumer products company. It offers eco-friendly diapers and a natural line of bath, skincare, home cleaning, and organic nutritional supplement products and other products.
Read more on HNST →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
